Previous 10 | Next 10 |
PTC Therapeutics (PTCT): Q4 GAAP EPS of -$1.08 misses by $0.15.Revenue of $118.86M (+23.2% Y/Y) beats by $5.04M.Reaffirms Full Year 2021 Guidance as Follows:PTC anticipates net product revenues for the DMD franchise for the full year 2021 to be between $355 and $375 million.PTC anticipates GA...
PTC Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update - $333 million 2020 total net product revenue representing 14% year-over-year growth - - Advancing multiple registration-directed clinical trials - - PTC518 healt...
PTC Therapeutics (NASDAQ:PTCT) is scheduled to announce Q4 earnings results on Thursday, February 25th, after market close.The consensus EPS Estimate is -$0.90 (vs. -$1.37 in year ago quarter) and the consensus Revenue Estimate is $113.82M (+18.0% Y/Y).Over the last 1 year, PTCT has beat...
Positive Data from FIREFISH Study of Evrysdi™ (risdiplam) in Infants with Type 1 Spinal Muscular Atrophy Published in The New England Journal of Medicine -- Results found that patients treated with Evrysdi at 12 months demonstrated significant improvements in survival and...
PTC Therapeutics Reports the Initiation of the Second Stage of the FITE19 Phase 2/3 Clinical Trial Evaluating PTC299 for the Treatment of COVID-19 -- PTC299 is an oral therapy that has a novel dual mechanism of action that inhibits viral replication and attenuates the uncontroll...
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results PR Newswire SOUTH PLAINFIELD, N.J. , Feb. 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webca...
PTC Therapeutics to Host Call to Review Results from its Study of Translarna™ (ataluren) in Patients with Nonsense Mutation Duchenne Muscular Dystrophy PR Newswire SOUTH PLAINFIELD, N.J. , Feb. 4, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (...
Risk~reward tradeoffs and net payoffs offered by this group are better than those of most S&P 500 Index stocks and of most other Market-Maker [MM] forecast securities. They also outdo the prospects of many stocks widely-held by Seeking Alpha readers, contributors, and commenters. ...
The following slide deck was published by PTC Therapeutics, Inc. in conjunction with this event. For further details see: PTC Therapeutics (PTCT) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow
PTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category - New category targets programs that support the transition from adolescence to adulthood - - Proposal submissions for 2021 STRIVE Awards are due March 15, 2021 - ...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....